Last reviewed · How we verify
Compound Edaravone Injection
Edaravone is a free radical scavenger that reduces oxidative stress and neuronal damage by neutralizing hydroxyl radicals and other reactive oxygen species.
Edaravone is a free radical scavenger that reduces oxidative stress and neuronal damage by neutralizing hydroxyl radicals and other reactive oxygen species. Used for Acute ischemic stroke, Amyotrophic lateral sclerosis (ALS).
At a glance
| Generic name | Compound Edaravone Injection |
|---|---|
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Drug class | Free radical scavenger / Antioxidant |
| Target | Hydroxyl radicals and reactive oxygen species |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Edaravone works by directly scavenging free radicals, particularly hydroxyl radicals generated during ischemic and reperfusion injury. By reducing oxidative stress in neural tissue, it limits secondary neuronal damage and apoptosis following acute ischemic stroke. This mechanism helps preserve neurological function and improve recovery outcomes in the acute phase of stroke.
Approved indications
- Acute ischemic stroke
- Amyotrophic lateral sclerosis (ALS)
Common side effects
- Injection site reactions
- Headache
- Nausea
- Fever
- Rash
Key clinical trials
- Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke (PHASE2)
- Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection (PHASE1)
- Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection (PHASE1)
- Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke (PHASE3)
- Compound Edaravone Injection for Acute Ischemic Stroke (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |